Novel agents for advanced pancreatic cancer

Akintunde Akinleye; Chaitanya Iragavarapu; Muhammad Furqan; Shundong Cang; Delong Liu

doi:10.18632/oncotarget.3999

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Novel agents for advanced pancreatic cancer

Akintunde Akinleye _, Chaitanya Iragavarapu, Muhammad Furqan, Shundong Cang and Delong Liu

PDF | HTML | How to cite

Oncotarget. 2015; 6:39521-39537. https://doi.org/10.18632/oncotarget.3999

Metrics: PDF 1792 views | HTML 3480 views | ?

Abstract

Akintunde Akinleye1, Chaitanya Iragavarapu1, Muhammad Furqan2, Shundong Cang3, Delong Liu4

1Division of Hematology/Oncology, Department of Medicine, New York Medical College, Valhalla, New York, United States

2Division of Hematology/Oncology, Department of Medicine, University of Iowa, Iowa City, Iowa, United States

3Department of Oncology, Henan Province People’s Hospital, Zhengzhou University, Zhengzhou, China

4Department of Oncology, Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

Correspondence to:

Delong Liu, e-mail: [email protected]

Keywords: pancreatic cancer, IGF-1R

Received: February 27, 2015 Accepted: May 20, 2015 Published: June 03, 2015

ABSTRACT

Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3999

Publication Alerts

Reviews:

Novel agents for advanced pancreatic cancer

Abstract